Santhera Pharma secures up to CHF 69M in financing for AGAMREE roll-out, European growth, and development.
Santhera Pharma secures up to CHF 69M in royalty and debt financing, including CHF 35M senior secured term loan from Highbridge and up to USD 38M from R-Bridge. This funding will aid in AGAMREE (vamorolone) roll-out, growth in Europe, and further developmental initiatives. Proceeds will help repay maturing bonds and fund strategic priorities, driving the company towards cash-flow break-even.
June 18, 2024
3 Articles